eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
NOWOŚĆ
Portal dla gastroenterologów!
www.egastroenterologia.pl
SCImago Journal & Country Rank
1/2018
vol. 13
 
Poleć ten artykuł:
Udostępnij:
więcej
 
 
streszczenie artykułu:
Artykuł oryginalny

Detection of hepatocellular carcinoma by tissue resonance interaction method (TRIM)

Grzegorz Boryczka, Marek Hartleb, Małgorzata Janik

Data publikacji online: 2018/03/26
Pełna treść artykułu
Pobierz cytowanie
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 


Introduction
Diagnosis of hepatocellular carcinoma (HCC) is considerably delayed, being frequently done in the non-curative stage of disease. The reason for delayed diagnosis is indolent course in early stages and/or unspecific symptoms indistinguishable from underlying cirrhosis. Hitherto methods used for screening of HCC have important limitations. TRIMprob is a non-invasive method, which showed utility in detection of cancers located in prostate, breast, or urinary bladder.

Aim
To determine the diagnostic accuracy of TRIMprob in detecting HCC in cirrhotic liver.

Material and methods
Forty-five patients were prospectively enrolled according to final clinical diagnosis into a group of cirrhosis and HCC or a group of cirrhosis without HCC. A control group consisted of 33 healthy subjects. Hepatocellular carcinoma was diagnosed by computed tomography (CT) or magnetic resonance (MR) and guided biopsy. The TRIMprob examination was performed in each patient. Three wave frequencies were used: 465, 930, and 1395 MHz.

Results
In patients with HCC the intensity of return signal using wave a frequency of 465 MHz was significantly reduced in patients with HCC in comparison to healthy subjects (p < 0.0005), but not to cirrhotic patients without HCC. Moreover, cirrhosis was associated with significantly decreased TRIMprob signal in comparison to healthy liver (p < 0.002). In ROC analysis an optimal cut-off value for detection of HCC was 106 units, which yielded 80% sensitivity.

Conclusions
TRIMprob identifies HCC with good sensitivity; however, the accuracy of this method to identify HCC in screening circumstances may be hindered by attenuation of the resonance interaction signal by cirrhosis itself.

referencje:
El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.
Llovet JM, Ducreux M, Lencioni R, et al. European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
Naghavi M. The global burden of cancer 2013. JAMA Oncol 2015; 1: 505-27.
Thun MJ, De Lancey JO, Center MM, et al. The global burden of cancer: priorities for prevention. Carcinogenesis 2010; 31: 100-10.
Vedruccio C, Meessen A. EM cancer detection by means of non-linear resonance interaction. Proceedings of the Progress in Electromagnetics Research Symposium (PIERS) 2004; Pisa, Italy, March 28-31: 909-12.
Pokorny J, Vedruccio C, Cifra M, et al. Cancer physics: diagnostics based on damped cellular elastoelectrical vibrations in microtubules. Eur Biophys J 2011; 40: 747-59.
Bellorofonte C, Vedruccio C, Tombolini P, et al. Non-invasive detection of prostate cancer by electromagnetic interaction. Eur Urol 2005; 47: 29-37.
Da Pozzo L, Scattoni V, Mazzoccoli B, et al. Tissue-resonance interaction method for the noninvasive diagnosis of prostate cancer: analysis of a multicentre clinical evaluation. BJU Int 2007; 100: 1055-9.
Tubaro A, de Nunzio C, Trucchi A, et al. The electromagnetic detection of prostatic cancer: evaluation of diagnostic accuracy. Urology 2008; 72: 340-4.
Gokce O, Sanli O, Salmaslioglu A, et al. Tissue resonance interaction method (TRIMprob) has the potential to be used alongside the recognized tests in the screening protocols for prostate cancer. Int J Urol 2009; 16: 580-3.
Di Viccaro D, Perugia G, Cerulli C, et al. The accuracy of tissue resonance interaction method probe (Trimprob) in non-invasive diagnosis of prostatic cancer. Analysis of the results of 782 patient. Urology 2009; 76 (Suppl 15): 1-3.
De Cicco C, Mariani L, Vedruccio C, et al. Clinical application of spectral electromagnetic interaction in breast cancer: diagnostic results of a pilot study. Tumor 2006; 92: 207-12.
Sacco R, Sammarco G, de Vinci R, et al. Relief of gastric cancer with an electromagnetic interaction system (TRIMprob) in outpatients. Sur Ital 2007; 59: 823-8.
Sacco R, Innaro N, Pata F, et al. Preoperative diagnosis of incidental carcinoma in multinodular goitre by means of electromagnetic interactions. Sur Ital 2007; 59: 247-51.
Vannelli A, Leo E, Battaglia L, et al. Diagnosis of rectal cancer by electromagnetic interactions: preliminary results. Dis Colon Rectum 2009; 52: 162-6.
Dore M, Tufano M, Pes G, et al. Tissue resonance interaction accurately detects colon lesions: a double-blind pilot study. World J Gastroenterol 2015; 21: 7851-9.
Gervino G, Autino E, Kolomoets E, et al. Diagnosis of bladder cancer at 465MHz. Electromag Biol Med 2007; 26: 119-34.
Cormio L, Vedruccio C, Leucci G, et al. Noninvasive electromagnetic detection of bladder cancer. Urology 2014; 2014: 802328.
Mourad A, Deuffic-Burban S, Ganne-Carrie N, et al. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Hepatology 2014; 59: 1471-81.
Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003; 39: 1076-84.
Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 2001; 20: 99-104.
Trevisani F, De Notariis S, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97: 734-44.
Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbsAg and anti-HCV status. J Hepatol 2001; 34: 570-5.
Di Bisceglie AM, Sterling RK, Chung RT, et al. HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005; 43: 434-41.
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe